![[IMNM] Biotech Absurdity](https://disruptivetr.com/wp-content/uploads/2021/01/2ndOrderCovid.jpg)
[IMNM] Biotech Absurdity
Low float stocks are prone to major moves on nominal volume. Unfortunately in both directions. Here’s what’s going on with IMNM…
![[IMNM] One Big Step Closer To Escape Velocity](https://disruptivetr.com/wp-content/uploads/2021/04/IMNM.Escape.jpg)
[IMNM] One Big Step Closer To Escape Velocity
The latest data out of Immunome underscores the superiority of its approach and demonstrates why the stock could be the next high-flying Novavax (NVAX)
![[IMNM] New Data Puts Us One Step Closer to $100+ Per Share](https://disruptivetr.com/wp-content/uploads/2020/04/ATOM.Blastoff.jpg)
[IMNM] New Data Puts Us One Step Closer to $100+ Per Share
The latest data out of Immunome underscores the superiority of its approach and demonstrates why the stock could be the next high-flying Novavax (NVAX)
![[IMNM] New Data Makes Stock A (Screaming) Buy](https://disruptivetr.com/wp-content/uploads/2021/02/2020-DTR-EMAIL-HEADER-IMAGES_SCREAM-1.jpg)
[IMNM] New Data Makes Stock A (Screaming) Buy
The latest data out of Immunome underscores the superiority of its approach and adds urgency to the opportunity. Here’s why…
[New Pick] Preparing For Second-Order Covid-19 Profits
With micro-caps surging and the Covid-19 pandemic underscoring the vital need for new drugs and therapies, this micro-cap is perfectly positioned to capitalize on the momentum in both areas of the market.